Cue Biopharma (CUE) Debt to Equity (2022 - 2025)
Cue Biopharma (CUE) has disclosed Debt to Equity for 4 consecutive years, with $0.12 as the latest value for Q3 2025.
- Quarterly Debt to Equity fell 40.35% to $0.12 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $0.12 through Sep 2025, down 40.35% year-over-year, with the annual reading at $0.25 for FY2024, 12.47% up from the prior year.
- Debt to Equity hit $0.12 in Q3 2025 for Cue Biopharma, down from $0.14 in the prior quarter.
- In the past five years, Debt to Equity ranged from a high of $0.51 in Q1 2025 to a low of $0.12 in Q3 2025.
- Historically, Debt to Equity has averaged $0.22 across 4 years, with a median of $0.21 in 2024.
- Biggest YoY gain for Debt to Equity was 113.72% in 2025; the steepest drop was 50.64% in 2025.
- Year by year, Debt to Equity stood at $0.15 in 2022, then surged by 44.64% to $0.22 in 2023, then grew by 12.47% to $0.25 in 2024, then crashed by 49.75% to $0.12 in 2025.
- Business Quant data shows Debt to Equity for CUE at $0.12 in Q3 2025, $0.14 in Q2 2025, and $0.51 in Q1 2025.